InsidersTradesSigma
申报总数
公司
▲ 买入（5 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
5
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-40.6%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the detailed record of transactions filed by HighCape Capital, L.P.. Director active across 2 companies, notably Aziyo Biologics, INC.. Cumulatively, 7 filings have been recorded. Breakdown: 5 buys · 0 sell. Total volume traded: €6.7m. History available since 8 December 2021. The latest transaction was disclosed on 3 February 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to HighCape Capital, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
420,000 股@ US$2.5021.2% 占其流量Class A Common StockSEC:0001104659-25-023488:0
标准退出：2025年5月4日 (T+90)
420,000 股@ US$2.5021.2% 占其流量Class A Common StockSEC:0001104659-25-023484:0
标准退出：2025年5月4日 (T+90)
2,101,577 股@ US$1.427557.5% 占其流量Class A Common StockSEC:0001104659-24-084967:0
1,436,077 股Class A Common StockSEC:0001104659-24-002239:0
2,837,128 股Class A Common StockSEC:0001826279-23-000002:0
标准退出：2021年12月20日 (T+90)
735,000 股@ US$4.7555.4% 占其流量Class A Common StockSEC:0001104659-22-125197:0
标准退出：2023年3月5日 (T+90)
353,773 股@ US$4.2428.7% 占其流量Class A Common StockSEC:0001104659-21-148591:0
标准退出：2022年3月8日 (T+90)
7 条申报中的 7 条
About HighCape Capital, L.P.
HighCape Capital, L.P. is a declarant linked to ELUTIA INC. and Aziyo Biologics, INC., where it is a director. It has 7 filings in total, and across the 7 sampled filings, buys amount to EUR 6690486 and sells to EUR 0, over the period from 2021-12-10 to 2025-03-13, with the modal transaction nature listed as Acquisition.
